Last reviewed · How we verify
Avenanthramide
At a glance
| Generic name | Avenanthramide |
|---|---|
| Sponsor | Montreal Heart Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single and Multiple Ascending Oral Doses of Avenanthramide (PHASE1, PHASE2)
- A Pilot Study Evaluating Oat Polyphenols on Post-prandial Glucose Response (NA)
- Avenanthramides and Exercise (NA)
- Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical (NA)
- Avenanthramide and Saponin Bioavailability in Oat Bran (NA)
- Phenolic-rich Oats and Artery Improvement (NA)
- Chronic Cardiovascular and Gut-bacteria Effects of Phenolic Rich Oats in Adults With Above Average Blood Pressure (NA)
- Effects of Avenanthramide-enriched Oats on Inflammation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avenanthramide CI brief — competitive landscape report
- Avenanthramide updates RSS · CI watch RSS
- Montreal Heart Institute portfolio CI